GlassScriptPhysician profile
Yijun Fan
NPI 1336161751
$29,826.94
in general payments reported to CMS, 2019-2025
39 companies · $5,083 in 2025
The $5,083 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,657 · 2020: $5,012 · 2021: $3,620 · 2022: $3,677 · 2023: $3,784 · 2024: $2,994 · 2025: $5,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,734 · Consulting Fee: $2,280 · Travel and Lodging: $447 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,733.87 |
| Consulting Fee | $2,280.00 |
| Travel and Lodging | $446.94 |
| Education | $399.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,482.99 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $4,446.58 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $3,556.33 | 2019-2025 | |
| Abbvie INC. | $3,375.01 | 2019-2025 | |
| Amgen INC. | $2,970.83 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Lilly USA, LLC | $1,250.67 | 2019-2025 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $1,047.41 | 2019-2025 | |
| Genentech USA, INC. | $913.96 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Glaxosmithkline, LLC. | $896.07 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $886.62 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $831.06 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $779.66 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $771.00 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Mallinckrodt Hospital Products INC. | $674.59 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $559.91 | 2021-2025 | Lupkynis |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $327.73 | 2023-2025 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.74 | 2019-2025 | Cyltezo, Ofev |
| Alexion Pharmaceuticals, INC. | $230.92 | 2020-2022 | |
| Octapharma USA, INC. | $225.99 | 2021-2025 | Octagam Immune Globulin (Human) |
| Janssen Scientific Affairs, LLC | $199.14 | 2020-2025 | Tremfya |
| Organon LLC | $178.03 | 2022-2025 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $168.08 | 2019 | |
| Progentec Diagnostics, INC. | $149.27 | 2023 | |
| Genzyme Corporation | $148.78 | 2019-2025 | |
| Kyowa Kirin, INC. | $47.09 | 2024-2025 | Crysvita |
| Tonix Medicines, INC. | $43.04 | 2025 | Tonmya |
| Celltrion USA INC. | $41.59 | 2023 | Yuflyma |
| Alvogen INC | $39.93 | 2023-2025 | Teriparatide |
| Azurity Pharmaceuticals, INC. | $39.86 | 2023-2024 | Horizant, Horizant |
| Mylan Institutional INC. | $39.68 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $38.09 | 2022-2023 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $34.18 | 2022-2023 | |
| Tersera Therapeutics LLC | $33.64 | 2025 | Quzyttir |
| Sandoz INC. | $32.84 | 2023 | Hyrimoz |
| Celgene Corporation | $27.82 | 2019 | |
| Medexus Pharma, INC. | $26.33 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $21.28 | 2024 | Arcalyst |
| Sobi, INC | $15.02 | 2025 | |
| Hikma Pharmaceuticals USA | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yijun Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.